Dimerix (ASX:DXB)
has initiated an important trial in Japan (with regard to patient enrollment) aimed at treating inflammatory conditions.
Tune into the HotCopper podcast for comprehensive debates and deep dives into this week’s major news stories.
Across platforms like Spotify, Apple, and others
.
The company’s ACTION 3 trial stands for: “Angiotensin II Type 1 Receptor (AT1R) and Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis.”
This is a Phase 3 clinical study focusing on participants using an angiotensin II receptor blocker and suffering from a kidney condition known as FSGS. Individuals meeting these criteria will receive DXB’s “DMX200,” which is the primary investigational drug being advanced by Dimerix.
Phase 3 trials are the major players for most countries’ health regulatory agencies; actually, the company is counting on the information gathered from ACTION3 to secure its route towards a future where it can market DMX200 globally.
As part of the trial, Dimerix will additionally be receiving $4.3 million from a partner upon reaching certain milestones.
Open the Youtube video
More market news
Trims:
The RBA rate cut was certain. China’s similar move highlights broader macroeconomic factors.
Meet GeoGeorge:
The HotCopper user was so precise in their insights that they were offered a job as an analyst.
“Launching the initial clinical site in Japan marks a significant advancement for our worldwide ACTION3 clinical program. We’re striving to deliver essential and innovative therapies to FSGS patients globally,” stated Dr. Nina Webster, CEO of DXB.
This achievement underscores the robustness of our current data, the thoroughness of our clinical trial setup, and the proficiency of our Japanese collaborator, FUSO.
DXB
last traded at 58cps.
Join the discussion:
See what
HotCopper
users are saying about
Dimerix
And join in the discussions that shape market trends.
The content of this article serves solely informational purposes and does not constitute investment advice. We encourage viewers to perform their due diligence and seek guidance from a qualified financial advisor prior to making any investment choices. To review our complete disclaimer details, kindly proceed by clicking.
here
.
